Syntara Limited (ASX:SNT)
Australia · Delayed Price · Currency is AUD | Market Cap | 45.76M -44.8% |
| Revenue (ttm) | 7.50M -8.0% |
| Net Income | -11.06M |
| EPS | -0.01 |
| Shares Out | 1.63B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,437,064 |
| Average Volume | 1,352,282 |
| Open | 0.0270 |
| Previous Close | 0.0280 |
| Day's Range | 0.0270 - 0.0280 |
| 52-Week Range | 0.0230 - 0.0830 |
| Beta | 0.14 |
| RSI | 34.68 |
| Earnings Date | May 8, 2026 |
About Syntara
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a P... [Read more]
Financial Performance
In fiscal year 2025, Syntara's revenue was 7.30 million, an increase of 26.61% compared to the previous year's 5.76 million. Losses were -7.92 million, -47.70% less than in 2024.
Financial StatementsNews
Syntara Transcript: Investor update
Formal FDA alignment on the phase II-B trial for imsulostat de-risks the clinical path and enhances partnering prospects. A recent AUD 8 million capital raise extends the cash runway to Q3 2027, funding multiple clinical milestones and supporting ongoing licensing discussions.
Syntara Transcript: NWR Virtual Healthcare Conference
Syntara highlighted its diversified late-stage pipeline, with multiple clinical readouts expected in the next 12 months. Lead asset amsulostat showed strong efficacy and safety in myelofibrosis, while skin scarring and Parkinson’s programs are advancing with significant commercial interest.
Syntara Transcript: Investor update
Entering 2026 with a strong cash position and five clinical trials, the pipeline is set for multiple data readouts, with amsulostat leading in myelofibrosis and MDS. Flexible partnering options and non-dilutive funding support broad optionality and capital efficiency.
Syntara Transcript: Study Update
Scarring remains a major unmet need with no approved therapies that remodel tissue at the biological level. SNT-9465, a next-generation pan-LOX inhibitor, showed promising safety and mechanistic results in early studies and is now in a rigorously designed phase 1b trial for hypertrophic sternotomy scars.
Syntara Transcript: AGM 2025
The meeting highlighted strong clinical progress, robust financial health, and a diversified pipeline with key data readouts expected in the next year. Voting was completed on all resolutions except one withdrawn item, and the company remains well positioned for future growth.
Syntara Transcript: Bell Potter Healthcare Conference 2025
The conference showcased Syntara's progress with its diverse clinical pipeline, highlighting strong efficacy and safety data for its lead asset in myelofibrosis, upcoming regulatory milestones, and multiple catalysts expected in 2025. Immutep was also introduced, with its lead immunotherapy in a global phase 3 lung cancer trial.
Syntara Transcript: Study Update
Final phase 2A data for amsulastat in myelofibrosis showed 73% of patients achieved major symptom reduction, with strong spleen volume responses and no drug-related withdrawals. Six of seven completers opted to continue treatment, and new expert advisors have joined to guide the next development phase.
Syntara Transcript: Investor Update
FDA guidance requires a separate phase II-B trial for amsulostat, extending timelines but providing a clear path to approval and supporting future partnering. Funding options remain robust, with a cash runway to 2027 and multiple ongoing studies expected to generate value.
Syntara Transcript: Study Result
Interim phase II data for SNT-5505 in advanced myelofibrosis show strong symptom and spleen volume improvements, with a favorable safety profile and no drug-related hematological toxicity. FDA fast-track status and upcoming regulatory discussions support advancement to phase III.
Syntara Earnings Call Transcript: Q3 2025
Strong cash reserves support an 18-month runway as multiple clinical programs advance, with key SNT-5505 myelofibrosis data to be presented at EHA in June and regulatory feedback expected in Q3. Skin scarring and Parkinson’s studies also progress, with data due next year.
Syntara Transcript: NWR Virtual Healthcare Conference
The conference highlighted a robust pipeline targeting fibrosis and blood cancers, with lead asset SNT 5505 showing strong efficacy and safety in myelofibrosis. Multiple studies are set to deliver key data in 2024, and new skin scarring and Parkinson’s programs are advancing.
Syntara Transcript: EGM 2025
The meeting covered four key resolutions related to share placements, director participation, advisor fees, and capacity refresh, with all votes conducted online. Updates were provided on clinical data timelines and pharma interest, and voting results will be released to the exchange.
Syntara Transcript: Study Result
Interim results for SNT5505 in myelofibrosis show strong symptom and spleen responses, with about 60% of patients achieving significant symptom improvement and a favorable safety profile. The drug may offer a competitive option for patients with limited alternatives.
Syntara Transcript: AGM 2024
The meeting highlighted a year of transformation, cost reduction, and strategic focus on advancing the lead asset SNT-5505, with new clinical studies and external funding secured. All resolutions were presented and voting conducted, with results to be released post-meeting.
Syntara Earnings Call Transcript: Q1 2025
Strong institutional backing, a diversified late-stage pipeline, and significant cost reductions position the company for key data readouts in December and throughout 2025, with a solid cash runway and multiple non-dilutive grants supporting ongoing studies.